Skip to main content
TipRanks
Go Ultimate75% OFF

Amgen (AMGN) AI Stock Analysis

7,051 Followers
AMGN

Amgen

(NASDAQ:AMGN)

Select Model
Rating:75Outperform
Price Target:$519.00▲(16.92% Upside)
Action:reiterated
Date:11/04/26

AMGN’s score is driven primarily by strong technical momentum and a very constructive earnings update (raised 2026 guidance, broad product growth, and positive late-stage pipeline progress). These positives are tempered by meaningful balance-sheet leverage risk and a valuation that is not cheap, though supported by a moderate dividend.

Positive Factors
Broad portfolio growthGrowth is broad rather than dependent on one product, with multiple therapies delivering double-digit gains and key drivers representing most product sales. This diversification supports more durable revenue expansion, improves commercial resilience, and gives Amgen a stronger base for continued investment.
Negative Factors
Heavy financial leverageHeavy leverage leaves Amgen more exposed if earnings weaken, because interest obligations and refinancing needs can absorb cash that might otherwise support innovation or shareholder returns. The relatively small equity base also amplifies financial risk when operating performance becomes less consistent.

Amgen Key Performance Indicators (KPIs)

Revenue by TypeDistinguishes between different revenue streams, such as product sales and royalties, providing insights into Amgen's business model and diversification.

$0.00$2.50B$5.00B$7.50B$10.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Product sales are the company’s growth engine—broad-based, accelerating and the main reason Amgen raised 2026 guidance—driven by multiple high-growth brands that more than offset the Prolia/XGEVA decline. “Other” revenue is much smaller and lumpy but has lifted recently, aligning with BD receipts and the $100M upfront that will bump Q3; don’t treat it as recurring. Key risks: higher cost-of-sales/profit-sharing and planned R&D/capex step-ups could pressure margins even as product-led top-line momentum continues.

Data provided by:The Fly

Amgen (AMGN) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%AMGN+35.50%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$240.11B
Dividend Yield
2.24%
Average Volume (3M)
2.76M
Price to Earnings (P/E)
25.5
Beta (1Y)
0.26
Revenue Growth
8.60%
EPS Growth
33.48%
Country
US
Employees
31,500
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Amgen Business Overview & Revenue Model

Company Description

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span...

How the Company Makes Money

Amgen makes money primarily by selling prescription medicines, with revenue largely driven by net product sales (gross sales minus rebates, chargebacks, returns, and other allowances common in pharmaceuticals). Its key revenue streams include: (1) Sa...

Amgen Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-3.77%|Next Earnings Date:Feb 09, 2027
Earnings Call SentimentPositive

The call was strongly optimistic, supported by 8% revenue growth, 27% growth from the six key growth drivers, broad product momentum, positive late-stage clinical results, strong free cash flow and raised 2026 revenue and EPS guidance. The principal negatives were a 6% TEPEZZA sales decline, expected fourth-quarter expense increases, higher full-year other expense guidance and some uncertainty around upcoming symptomatic Sjogren's data and international MariTide reimbursement. Highlights significantly outweighed the lowlights.

Positive Updates

Broad Revenue Growth and Portfolio Momentum
Third-quarter total revenues grew 8% year-over-year to $10.4 billion. The six key growth drivers grew 27% year-over-year and represented more than 70% of third-quarter product sales. Across the portfolio, 17 products delivered double-digit sales growth, and 17 products were annualizing at more than $1 billion based on third-quarter sales.

Negative Updates

TEPEZZA Sales Decline
TEPEZZA generated $526 million in third-quarter sales, a 6% decline year-over-year, impacted by an inventory build in the third quarter of the prior year.

Company Guidance

For 2026, Amgen now expects total revenues in the range of $38.9 billion to $39.7 billion and non-GAAP earnings per share between $22.90 and $23.70; non-GAAP other income and expense is expected to be in the range of $2 billion to $2.1 billion of expense, full-year non-GAAP operating margin as a percentage of product sales is expected to be roughly 45% to 46%, other revenue is expected to be approximately $1.9 billion, the non-GAAP tax rate is expected to be in the range of 15% to 16.5%, share repurchases are expected not to exceed $3 billion, and capital expenditures are expected to be approximately $2.6 billion. For the fourth quarter, Amgen expects a meaningful sequential increase in operating expenses, including a sequentially higher cost of sales margin and higher SG&A expense. Looking ahead to 2027, Amgen does not anticipate a step-down in operating margin compared with its 2026 guidance.

Amgen Financial Statement Overview

Summary

Strong profitability and cash generation support the score (TTM gross margin ~74%, net margin ~24%, operating cash flow ~$12B and free cash flow ~$9.6B). The main offset is balance-sheet risk: leverage is high (TTM debt-to-equity ~3.8x; total debt ~$54B) and profitability/free cash flow have shown some volatility.

Income Statement

84Very Positive

Balance Sheet

43Neutral

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue38.90B36.74B33.42B28.19B26.32B25.98B
Gross Profit27.88B26.01B20.57B19.77B19.92B19.52B
EBITDA18.17B16.90B13.36B14.80B12.17B11.30B
Net Income9.39B7.71B4.09B6.72B6.55B5.89B
Balance Sheet
Total Assets96.05B90.59B91.84B97.15B65.12B61.16B
Cash, Cash Equivalents and Short-Term Investments13.19B9.13B11.97B10.94B9.30B8.04B
Total Debt54.01B54.60B60.10B64.61B38.95B33.31B
Total Liabilities81.70B81.93B85.96B90.92B61.46B54.47B
Stockholders Equity14.35B8.66B5.88B6.23B3.66B6.70B
Cash Flow
Free Cash Flow9.58B8.10B10.39B7.36B8.79B8.38B
Operating Cash Flow12.04B9.96B11.49B8.47B9.72B9.26B
Investing Cash Flow-2.63B-1.94B-1.05B-26.20B-6.04B733.00M
Financing Cash Flow-5.66B-10.86B-9.41B21.05B-4.04B-8.27B

Amgen Technical Analysis

Technical Analysis SentimentNeutral
Last Price443.89

Price Trends

50DMA428.15Positive
100DMA412.43Positive
200DMA380.25Positive

Market Momentum

MACD7.68Positive
RSI45.69Neutral
STOCH25.91Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMGN, the sentiment is Neutral. The current price of 443.89 is below the 20-day moving average (MA) of 458.95, above the 50-day MA of 428.15, and above the 200-day MA of 380.25, indicating a neutral trend. The MACD of 7.68 indicates Positive momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 25.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMGN.

Amgen Risk Analysis

Amgen disclosed 32 risk factors in its most recent earnings report. Amgen reported the most risks in the "Ability to Sell" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Ability to Sell - Risks related to the company’s ability to sell goods and services

Latest Risks Added

3 New Risks
1.Post-approval PhaseQ3, 2026
2.Genesis Health Care, Inc. v. BecerraQ3, 2026
3.Concentration of sales at certain of our wholesaler distributors and consolidation of private payers, such as insurers and PBMs, have negatively affected, and may continue to negatively affect, our business. -Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our productsQ3, 2026

Amgen Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AMGN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AMGNAMGN75Outperform$240.11B25.5485.59%2.24%8.60%33.48%
NVSNVS72Outperform$289.35B30.0024.24%3.05%1.64%-28.72%
ABBVABBV71Outperform$505.56B49.05-202.35%2.42%10.68%338.08%
JNJJNJ70Outperform$670.92B41.3419.55%1.94%7.81%-35.95%
BMYBMY66Neutral$125.40B13.1843.88%4.23%4.19%52.55%
MRKMRK64Neutral$339.66B139.175.29%2.47%5.21%-86.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%20%40%60%AMGNBMYJNJMRKNVSABBVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AMGN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AMGNAmgen Inc443.89113.1234.20%
BMYBristol-Myers Squibb Company59.5615.2834.51%
JNJJohnson & Johnson272.7073.2936.76%
MRKMerck & Company137.7842.8145.08%
NVSNovartis AG155.2130.3524.30%
ABBVAbbvie286.0156.6024.67%

Amgen Corporate Events

Business Operations and StrategyExecutive/Board Changes

Amgen Adds David Gibbs to Board of Directors

Positive
Oct 27, 2026

On Oct. 26, 2026, Amgen appointed David W. Gibbs, the recently retired president and chief executive officer of Yum! Brands, to its Board of Directors, effective immediately. Gibbs joins the Audit Committee and the Compensation and Management Develop...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026